Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$4.3B
60M shares
52-week range
$59.74 – $96.74
26% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $882.8M | $994.9M | $963.9M | $1.07B | $1.15B | $1.26B | $1.36B | $1.51B |
| Cost of revenue | $488.0M | $562.5M | $562.7M | $589.4M | $631.9M | $673.5M | $713.2M | $777.8M |
| Gross profit | $394.8M | $432.4M | $401.2M | $485.3M | $519.1M | $583.9M | $643.3M | $736.9M |
| Gross margin | 44.7% | 43.5% | 41.6% | 45.2% | 45.1% | 46.4% | 47.4% | 48.7% |
| R&D | $59.5M | $65.6M | $57.5M | $71.2M | $75.5M | $82.7M | $83.8M | $97.4M |
| Operating income | $58.6M | $15.4M | −$1.6M | $60.9M | $87.6M | $123.9M | $155.7M | $184.4M |
| EBITDA | $129.4M | $119.3M | $103.6M | $155.0M | $181.2M | $228.9M | $274.0M | $332.0M |
| Net income | $42.0M | $5.5M | −$9.8M | $48.5M | $74.5M | $94.4M | $120.4M | $128.5M |
| Net margin | 4.8% | 0.5% | -1.0% | 4.5% | 6.5% | 7.5% | 8.9% | 8.5% |
| EPS (diluted) | 0.78 | 0.10 | -0.18 | 0.84 | 1.29 | 1.62 | 2.03 | 2.13 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.6B | $4.07 | $4.05–$4.08 | 7 |
| 2027 | $1.7B | $4.40 | $4.28–$4.53 | 7 |
| 2028 | $1.8B | $4.74 | $4.23–$5.41 | 3 |
| 2029 | $1.9B | $5.03 | $4.98–$5.07 | 1 |
Forward consensus · source: Financial Modeling Prep
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
www.merit.comNo one on the platform currently holds MMSI.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 314,212 | $21.7M |
| Bridgewater Associatesas of 2026-03-31 | 5,507 | $379.6K |
| Execution date | Ratio |
|---|---|
| 2011-05-06 | 5-for-4 |
| 2003-12-03 | 4-for-3 |
| 2003-08-15 | 4-for-3 |
No one on the platform has traded MMSI yet.
| $8.2B |
| — |
| KRYSKrystal Biotech, Inc. | $371.67 | -1.71% | $11.0B | — |
| PTCTPTC Therapeutics, Inc. | $81.57 | +0.00% | $6.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 34.0× earnings vs its 45.2× historical median P/E.
Fair value ≈ $92.30 · price $69.34 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
HIGH CONFIDENCE 🔥🚨 $MMSI 75 CALL 7/17 avg .80🚨 All trades are shared https://t.me/veltrixcapitalbrokers
View on StockTwits ↗KeyBanc just highlighted $MMSI as a top medical device pick as Merit Medical secures expanded FDA breakthrough designations for its localized micro-catheter therapeutic pipelines. The weekly chart has spent weeks absorbing float directly against our primary line in the sand, positioning the tape for a major momentum shift ahead of the mid-year healthcare rebalancings. 🔬🛰️ 🎯 Levels to Confirm: 🐂 Bulls: $MMSI must claim and defend $82.16 on a closing print to break the corrective base and target a run back to $89.50. 🐻 Bears: $MMSI need to force a hard rejection at resistance to target a markdown flush below the $54.17 support shelf. #MedicalDevices #BioTech #MMSI #TechnicalAnalysis #hovdid
View on StockTwits ↗$MMSI Current Stock Price: $61.16 Contracts to trade: $60.0 MMSI May 15 2026 Call Entry: $1.15 Exit: $1.93 ROI: 68% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$MMSI CEO purchased 2,000 shares at $60.44 for a total of $120,880. Aronson Martha Goldberg now owns 49,792 shares. https://ceo-buys.com
View on StockTwits ↗$MMSI Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.69 up 35.29% YoY • Reported revenue of $381.88M up 7.46% YoY • Merit anticipates Total Revenue for the year ending December 31, 2026, to be $1.612-$1.634 billion, representing a 6%-8% year-over-year change, and Non-GAAP Earnings Per Share to be $4.01-$4.15, a 5%-8% change.
View on StockTwits ↗$MMSI reports after the close, Estimize Consensus +0.03 EPS and +3.37M Revs compared to WS http://www.estimize.com/mmsi/fq1-2026?utm_conten
View on StockTwits ↗$MMSI Share Price: $67.84 Contract Selected: Dec 18, 2026 $60 Calls Buy Zone: $11.30 – $13.97 Target Zone: $20.94 – $25.60 Potential Upside: 75% ROI Time to Expiration: 239 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$MMSI Merit Medical continues its tuck‑in roll‑up: $140M for View Point’s OneMark tumor localization system. Adds an ultrasound‑based, wire‑free option beside SCOUT and is expected to add ~$14–16M revenue in 2027. https://prismmarketview.com/merit-medical-adds-view-point-in-140m-deal-to-deepen-oncology-portfolio/
View on StockTwits ↗$MMSI catching a strong tailwind — but there’s a catch. Merit Medical is riding solid cardiovascular demand and fast-growing therapeutic devices, a combo fueling the bullish case. But tariffs, OEM weakness, and China macro pressures are real clouds investors shouldn’t ignore. ⚠️ See the full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2883254/heres-why-you-should-add-merit-medical-stock-to-your-portfolio-now?cid=sm-stocktwits-2-2883254-teaser-37202&ADID=SYND_STOCKTWITS_TWEET_2_2883254_TEASER_37202
View on StockTwits ↗$MMSI down 18.1% in six months — is a rebound on the horizon? 📉 Merit Medical is banking on its cardiovascular devices, projecting 5-7% revenue growth for 2026, driven by rising cardiovascular procedure volumes globally, despite tariff and China-related pressures. 🚀 Opportunity assessment here 👉 https://www.zacks.com/stock/news/2883254/heres-why-you-should-add-merit-medical-stock-to-your-portfolio-now?cid=sm-stocktwits-2-2883254-body-37203&ADID=SYND_STOCKTWITS_TWEET_2_2883254_BODY_37203
View on StockTwits ↗$MMSI beats expectations — what drove the surge? 🚀 Merit Medical posted a Q4 EPS of $1.04, topping the Zacks Consensus Estimate by 8.3%, with revenue growth in most areas except for OEM. U.S. and EMEA regions showed impressive gains, and both margins expanded, boosting investor confidence. Discover the full earnings breakdown here 👉 https://www.zacks.com/stock/news/2875413/merit-medical-q4-earnings-revenues-beat-estimate-margins-expand?cid=sm-stocktwits-2-2875413-body-35200&ADID=SYND_STOCKTWITS_TWEET_2_2875413_BODY_35200
View on StockTwits ↗$MMSI quietly delivered the kind of quarter bulls love. 💪 Q4 EPS climbed 12%, earnings and revenues beat estimates, and margins expanded — powered by strong Cardiovascular growth and solid U.S. and EMEA sales. That’s operating leverage showing up where it counts. Momentum building here? Full breakdown 👉 https://www.zacks.com/stock/news/2875413/merit-medical-q4-earnings-revenues-beat-estimate-margins-expand?cid=sm-stocktwits-2-2875413-teaser-35199&ADID=SYND_STOCKTWITS_TWEET_2_2875413_TEASER_35199
View on StockTwits ↗$MMSI Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.64 up 33.33% YoY • Reported revenue of $393.94M up 10.92% YoY • Merit Medical Systems, Inc. anticipates total revenue for fiscal year 2026 to be $1.61B to $1.63B, representing 6%-8% year-over-year growth on a reported basis, and Non-GAAP EPS of $4.01 to $4.15, up 5%8%.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.